biotech · Solid Tumors · Pancreatic Cancer · MREO
MEREO BIOPHARMA GROUP
Mereo BioPharma Group plc
MEREO BIOPHARMA GROUP is a biotech organization headquartered in LONDON, USA. It trades on NYSE under ticker MREO. Primary therapeutic focus areas include Solid Tumors, Pancreatic Cancer, Osteogenesis Imperfecta, Metasta
4TH FLOOR, ONE, LONDON, USA HQ
4 Employees
Public company Type
MREO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4TH FLOOR, ONE, LONDON, USA
- Employees
- 4
- Programs
- 47
- Drugs
- 22
- Patents
- 18
OMP-59R5
Phase 2 · small molecule · Stage IV Small Cell Lung Cancer
OMP-59R5 for Stage IV Small Cell Lung Cancer is a Phase 2 program (small_molecule) at Mereo BioPharma Group plc with 1 ClinicalTrials.gov record(s).
Internal code 59R5-003
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Mereo BioPharma Group plc
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Stage IV Small Cell Lung Cancer
- Status
- terminated
- Trials
- 1